Drug*placebo interaction effect may bias clinical trials interpretation: hybrid balanced placebo and randomized placebo-controlled design

被引:8
|
作者
Hammami, Muhammad M. [1 ,2 ]
Hammami, Safa [1 ]
Al-Swayeh, Reem [1 ]
Al-Gaai, Eman [1 ]
Farah, Faduma Abdi [1 ]
De Padua, Sophia J. S. [1 ]
机构
[1] King Faisal Specialist Hosp & Res Ctr, Dept Clin Studies & Empir Eth, POB 3354,MBC 03, Riyadh 11211, Saudi Arabia
[2] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia
来源
BMC MEDICAL RESEARCH METHODOLOGY | 2016年 / 16卷
关键词
Balanced placebo design; Randomized placebo-controlled trials; Biased drug effect size; Drug placebo interaction; Effect modification;
D O I
10.1186/s12874-016-0269-1
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Conventional randomized placebo-controlled study design assumes the absence of drug*placebo interaction. We hypothesized the presence of such an interaction and that conventionally estimated drug effect might be biased. The objectives of the study were to determine the drug*placebo interaction effect (main) and compare conventionally estimated and interaction model-estimated drug effects (secondary). Methods: We used a hybrid of balanced placebo and randomized placebo-controlled designs. Four hundred eighty healthy volunteers were randomized to three groups. The first received hydroxyzine (25 mg) described as hydroxyzine or placebo, the second received placebo described as hydroxyzine or placebo, and the third received hydroxyzine and placebo described as unknown; each in a randomized crossover design. Seven participants failed to crossover. Group assignment was concealed from participants and study coordinators. Coordinators were blinded to group and intervention assignment. Participants and coordinators were deceived as to study objectives. Main outcomes were mean area-under-the-curve of drowsiness (therapeutic outcome) and mouth-dryness (adverse outcome), self-reported on 100 mm visual analog scale over 7 h. Drug, placebo, placebo + interaction, and total effects were estimated using analysis of covariance by comparing received hydroxyzine/told placebo to received placebo/told placebo, received placebo/told hydroxyzine to received placebo/told placebo, received hydroxyzine/told hydroxyzine to received hydroxyzine/told placebo, and received hydroxyzine/told hydroxyzine to received placebo/told placebo, respectively. Drug effect was also conventionally estimated in the third group. Results: Mean (SD) age was 31.4 (6.6) years, 65% were males. There was significant difference between placebo + interaction effect and placebo effect for both drowsiness and mouth-dryness with a mean difference (95% confidence interval) of 35.1 (5.6 to 64.6) and 23.8 (2.4 to 45.2) mm*hr, respectively. Total effect was larger than the sum of drug and placebo effects for drowsiness (139.7 (109.8 to 169.6) vs. 99.1 (68.2 to 130.0) mm*hr) and mouth-dryness (63.6 (41.1 to 86.1) vs. 34.7 (11.1 to 58.4) mm*hr). Conventionally estimated drug effect was larger than interaction model-estimated drug effect for drowsiness (69.2 (45.5 to 92.8) vs. (58.3 (31.6 to 85.0) mm*hr) and mouth-dryness (19.9 (5.3 to 34.5) vs. 9.5 (-9.2 to 28.1) mm*hr). Conclusions: There is significant and important drug*placebo interaction effect that may bias conventionally estimated drug effect.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Placebo-controlled clinical trials: how trial documents justify the use of randomisation and placebo
    Tapani Keränen
    Arja Halkoaho
    Emmi Itkonen
    Anna-Maija Pietilä
    BMC Medical Ethics, 16
  • [42] Placebo-controlled clinical trials: how trial documents justify the use of randomisation and placebo
    Keranen, Tapani
    Halkoaho, Arja
    Itkonen, Emmi
    Pietila, Anna-Maija
    BMC MEDICAL ETHICS, 2015, 16
  • [43] Are the clinical effects of homoeopathy placebo effects? A meta-analysis of placebo-controlled trials
    Linde, K
    Clausius, N
    Ramirez, G
    Melchart, D
    Eitel, N
    Hedges, LV
    Jonas, WB
    LANCET, 1997, 350 (9081): : 834 - 843
  • [44] Interaction between drug and placebo effects: a cross-over balanced placebo design trial
    Hammami, Muhammad M.
    Al-Gaai, Eman A.
    Alvi, Syed
    Hammami, Muhammad B.
    TRIALS, 2010, 11
  • [45] Interaction between drug and placebo effects: a cross-over balanced placebo design trial
    Muhammad M Hammami
    Eman A Al-Gaai
    Syed Alvi
    Muhammad B Hammami
    Trials, 11
  • [46] The crossover design for migraine preventives: an analyses of four randomized placebo-controlled trials
    Jenssen, Astrid Bjorke
    Stovner, Lars Jacob
    Tronvik, Erling
    Sand, Trond
    Helde, Grethe
    Gravdahl, Goril Bruvik
    Hagen, Knut
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (01):
  • [47] Ethical considerations in placebo-controlled randomised clinical trials
    Kaufman, Kenneth R.
    BJPSYCH OPEN, 2015, 1 (01): : E3 - E4
  • [48] Social psychological factors in placebo-controlled clinical trials
    Gotay, Carolyn C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) : 1206 - 1207
  • [49] The crossover design for migraine preventives: an analyses of four randomized placebo-controlled trials
    Astrid Bjørke Jenssen
    Lars Jacob Stovner
    Erling Tronvik
    Trond Sand
    Grethe Helde
    Gøril Bruvik Gravdahl
    Knut Hagen
    The Journal of Headache and Pain, 2019, 20
  • [50] Nutraceutical Combinations in Hypercholesterolemia: Evidence from Randomized, Placebo-Controlled Clinical Trials
    Protic, Olga
    Bonfigli, Anna Rita
    Antonicelli, Roberto
    NUTRIENTS, 2021, 13 (09)